Marinus Pharmaceuticals Inc (NASDAQ:MRNS) fell 9.7% during trading on Friday . The company traded as low as $6.60 and last traded at $6.95. 4,340,283 shares were traded during mid-day trading, an increase of 157% from the average session volume of 1,690,370 shares. The stock had previously closed at $7.69.

A number of brokerages have commented on MRNS. ValuEngine raised Marinus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. JMP Securities reissued an “outperform” rating and issued a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th.

The stock’s market capitalization is $181.09 million. The company’s 50 day moving average price is $4.24 and its 200 day moving average price is $2.22.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.06. Equities analysts expect that Marinus Pharmaceuticals Inc will post ($0.74) EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of MRNS. Nexthera Capital LP purchased a new stake in shares of Marinus Pharmaceuticals in the 1st quarter worth approximately $1,416,000. Jennison Associates LLC grew its stake in shares of Marinus Pharmaceuticals by 108.1% in the 2nd quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after buying an additional 421,600 shares during the last quarter. Finally, KCG Holdings Inc. grew its stake in shares of Marinus Pharmaceuticals by 29.5% in the 1st quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 14,692 shares during the last quarter. Institutional investors own 23.61% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/08/marinus-pharmaceuticals-inc-mrns-trading-down-9-7.html.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Stock Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.